55.95
-15.7(-21.91%)
Currency In USD
| Previous Close | 71.65 |
| Open | 71.63 |
| Day High | 73.97 |
| Day Low | 40 |
| 52-Week High | 99.5 |
| 52-Week Low | 30.82 |
| Volume | 4.98M |
| Average Volume | 577,259 |
| Market Cap | 2.11B |
| PE | -10.42 |
| EPS | -5.37 |
| Moving Average 50 Days | 81.31 |
| Moving Average 200 Days | 67.81 |
| Change | -15.7 |
If you invested $1000 in Disc Medicine, Inc. (IRON) since IPO date, it would be worth $659.32 as of February 13, 2026 at a share price of $67.91. Whereas If you bought $1000 worth of Disc Medicine, Inc. (IRON) shares 5 years ago, it would be worth $539.83 as of February 13, 2026 at a share price of $67.91.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
GlobeNewswire Inc.
5 hours ago
FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the PPIX biomarker in protoporphyriaFDA indicated
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
GlobeNewswire Inc.
Jan 12, 2026 9:30 PM GMT
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
GlobeNewswire Inc.
Jan 12, 2026 1:30 PM GMT
Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia expected in H2 2026, followed by an